Laurus Labs has reported unprecedented growth for its fourth quarter and financial year ended March 2020, specifically for its generics business. While the company’s generic formulations business saw higher sales from low- and middle-income country tenders, contributing almost 30% of total revenue for the year that grew by 24% to INR28.32bn ($372m), its anti-viral offering in the generic active pharmaceutical ingredient segment also saw “stable revenues” and showed “robust growth.”
The anti-viral API revenues grew on a sequential basis for Laurus. “We expect this business to achieve stable revenues in...







